ABBV-319 also showed durable anti-tumor activity across multiple B-cell lymphoma PDX models, including non-germinal center B-cell (GCB) DLBCL and relapsed lymphoma post R-CHOP treatment. Collectively, these data support the ongoing evaluation of ABBV-319 in Phase I clinical trial (NCT05512390).

8 months ago

Journal

CD34 (CD34 molecule) • IL15 (Interleukin 15)

Rituxan (rituximab) • ABBV-319

11ms

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)

P1, N=114, Recruiting, AbbVie | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027

11 months ago

Trial completion date • Trial primary completion date • Adverse events

ABBV-319

over1year

P1, N=114, Recruiting, AbbVie | Not yet recruiting --> Recruiting | Trial completion date: Sep 2026 --> Feb 2026 | Initiation date: Aug 2022 --> Apr 2023 | Trial primary completion date: Sep 2026 --> Feb 2026

over 1 year ago

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Adverse events

ABBV-319

almost2years

Preclinical development of ABBV-319: a CD19-targeting glucocorticoid receptor modulator (GRM) agonist antibody-drug conjugate (ADC) for the treatment of B-cell malignancies (AACR 2023)

Introduction: Glucocorticoids are key components of standard-of-care treatment regimens (e.g., R-CHOP, Hyper-CVAD) for several B-cell malignancies. ABBV-319 has potent anti-tumor activity from three distinct MoA and exhibits safety improvements compared to systemic glucocorticoids, supporting its recent progression into Phase I clinical trial.

almost 2 years ago

Preclinical

CD34 (CD34 molecule) • IL15 (Interleukin 15)

Rituxan (rituximab) • ABBV-319